Berlin, Germany – In a significant development for public health in France, the government has extended reimbursement coverage for the Nimenrix vaccine, protecting a wider range of children against invasive meningococcal disease. This decision, published in the Journal officiel on February 20, 2026, ensures financial accessibility to the vaccine for children born in 2020, 2021 and 2022, bolstering national efforts to combat this potentially life-threatening infection. The move addresses a previous gap in coverage, as reimbursement hadn’t been fully implemented despite the vaccine’s inclusion in the national vaccination schedule.
Meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (blood poisoning). It’s a particularly serious concern for infants and young children. There are several serogroups of the bacteria, with A, B, C, W, and Y being the most common causes of severe infections. The recent shift in epidemiology, with a resurgence of serogroup B and expansion of serogroups W and Y, prompted a review of France’s vaccination strategy, leading to the current changes. According to data from Santé publique France, approximately 500 people in France are affected by invasive meningococcal infections each year. The majority of these infections in recent years have been caused by serogroup B (44% of cases in 2022) followed by W (29%) and Y (24%).
Expanded Vaccination Schedule and Reimbursement Details
Since January 1, 2025, vaccination against meningococcal serogroups ACWY has been mandatory for all infants in France up to the age of two. This replaced the previous obligation for vaccination against serogroup C. The recommended schedule involves an initial dose of Nimenrix at six months of age, followed by a booster dose at twelve months, with a minimum interval of two months between doses. The newly announced reimbursement applies to children born in 2020, 2021, and 2022 who may require a catch-up dose. A single dose of Nimenrix is sufficient for catch-up vaccination, regardless of whether the child has previously received a dose against meningococcal serogroup C.
The French Assurance Maladie will cover 65% of the cost of the Nimenrix vaccine. The remaining portion is typically covered by complementary health insurance (mutuelles). This financial support is crucial in ensuring equitable access to vaccination for all families. It’s important to note that other ACWY vaccines are also available, including MenQuadfi (approved for employ from 12 months of age) and Menveo (approved from 2 years of age). Reimbursement for MenQuadfi and Menveo has been in place since late 2024 for children at specific risk, and these vaccines are also reimbursed for adolescents aged 11-14 and as part of a catch-up campaign for those aged 15-24.
Understanding the Different Meningococcal Vaccines
The landscape of meningococcal vaccines can be complex. Beyond Nimenrix, MenQuadfi, and Menveo for serogroups ACWY, vaccines targeting serogroup B are also available. Bexsero is currently reimbursed for individuals aged 15-24 who choose to be vaccinated. Two doses are required, spaced at least one month apart, starting from the age of two. Another vaccine against serogroup B, Trumemba, is indicated for individuals aged 10 and older and is also reimbursed for those aged 15-24 and individuals at increased risk. Currently, Bexsero is not reimbursed for children between the ages of 2, and 5.
The development and implementation of these vaccination strategies are based on recommendations from the Haute Autorité de Santé (HAS), France’s national health authority. The HAS regularly reviews epidemiological data and adjusts vaccination recommendations to optimize public health outcomes. The decision to prioritize vaccination against serogroup B and ACWY reflects the changing patterns of meningococcal disease in France, as highlighted by surveillance data from Santé publique France.
The Importance of Meningococcal Vaccination
Meningococcal disease can progress rapidly and cause severe complications, including brain damage, hearing loss, limb amputation, and even death. Early diagnosis and treatment with antibiotics are crucial, but vaccination remains the most effective way to prevent infection. The bacteria are spread through close contact, such as coughing, sneezing, and kissing. While anyone can contract the disease, certain groups are at higher risk, including infants, young children, adolescents, and individuals with weakened immune systems.
The capsule surrounding the meningococcus is a key factor in its virulence, allowing it to evade the human immune system. The composition of this capsule determines the serogroup of the bacteria. Vaccines work by stimulating the body to produce antibodies that recognize and neutralize the capsule, preventing the bacteria from causing infection. Different vaccines use different antigens to target specific serogroups. For example, vaccines against serogroups A, C, W, and Y utilize the capsular polysaccharide, while different antigens are used to create the vaccine against serogroup B.
Who Can Administer the Vaccine?
In France, the vaccination against meningococcal serogroups B and ACWY can be administered by several healthcare professionals, including general practitioners, pediatricians, midwives, and nurses – with a medical prescription for nurses. This broad accessibility aims to facilitate widespread vaccination coverage and protect the population from this serious disease. The availability of multiple vaccination providers ensures that families have convenient options for accessing this vital preventative measure.
The recent changes in vaccination policy and reimbursement coverage represent a significant step forward in protecting the health of children and adolescents in France. By expanding access to these life-saving vaccines, the government is demonstrating its commitment to preventing the devastating consequences of meningococcal disease. The ongoing surveillance efforts of Santé publique France will continue to inform vaccination strategies and ensure that they remain effective in the face of evolving epidemiological trends.
The next key development to watch for will be any updates regarding reimbursement for the Bexsero vaccine for children aged 2-5, as well as ongoing monitoring of the effectiveness of the current vaccination program. Families are encouraged to consult with their healthcare providers to ensure their children are up-to-date on their vaccinations and to address any concerns they may have.
Do you have questions about meningococcal vaccination? Share your thoughts and experiences in the comments below. Please also share this article with your network to help raise awareness about this important public health issue.